Source comparison
Mechanistic Comparison Summary
Primary receptor No identified receptor; FAK intracellular activation FPR2; EGFR (transactivation); CXCR2/4 Primary wound biology Angiogenesis; fibroblast migration; collagen synthesis Re-epithelialisation; antimicrobial; neutrophil/monocyte recruitment Fibrob
This comparison does not assign a generated winner or score.
- Primary receptor
- No identified receptor; FAK intracellular activation
- FPR2; EGFR (transactivation); CXCR2/4
- Primary wound biology
- Angiogenesis; fibroblast migration; collagen synthesis
- Re-epithelialisation; antimicrobial; neutrophil/monocyte recruitment
- Fibroblast migration
- 22 µm/h (superior)
- 12 µm/h (moderate)
- Keratinocyte closure
- 11 µm/h (moderate)
- 18 µm/h (superior)
- Angiogenesis (CD31+)
- +113% above vehicle (superior)
- +50% above vehicle
- Direct antimicrobial
- None
- S. aureus −82–88%; MRSA −72–78%; biofilm −58–64%
- db/db wound closure day14
- 68%
- 74%
- Combination closure day14
- 88% (additive via orthogonal mechanisms)
- Key blocker
- PF-573228 (FAK); L-NAME (eNOS)
- WRW4 (FPR2); erlotinib (EGFR)
- Optimal use case
- Non-infected chronic wound; tendon/ligament; systemic tissue repair
- Infected wound; biofilm; re-epithelialisation; post-debridement coverage
- Sequential protocol
- LL-37 days 0–5 (antimicrobial clearance) → BPC-157 days 5–21 (granulation/angiogenesis)
- 🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified BPC-157 and LL-37 for research and laboratory use. View UK stock →
- William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.